A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

NCT00171990

Recurrent Genital Herpes

COMPLETED PHASE3

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

NCT00248144

Recurrent Herpes Labialis

COMPLETED PHASE4

RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

NCT00219310

Recurrent Genital Herpes (RGH)

COMPLETED PHASE4

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072

Herpes Labialis

COMPLETED PHASE2/PHASE3

Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

NCT01154543

HIV Positive Herpes Simplex, Genital

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genital Herpes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Famciclovir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

Exclusion Criteria

* Pregnancy
* History of renal dysfunction
* Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
* Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No